Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

German HTA Assessment Knocks Back Gilenya In Europe

This article was originally published in The Pink Sheet Daily

Executive Summary

IQWiG’s failure to find any added benefit from Novartis’ oral MS drug Gilenya in two out of three of its target patient groups, on the grounds of insufficient evidence, puts pressure on the drug following a similarly negative recommendation by U.K. cost-watchdog NICE at the end of 2011.

You may also be interested in...



EMA Passes GSK’s Mekinist, Extends Indications For Gilenya And Pradaxa

The EMA recommended authorizing a single drug this month, GSK’s Mekinist, while giving the nod to seven others, including Novartis’ Gilenya and Boehringer Ingelheim’s Pradaxa.

Sanofi’s Aubagio And Biogen Idec’s Tecfidera Make It A Good Day For MS Sufferers At EMA

The EMA’s CHMP has given the nod to Sanofi’s Aubagio and Biogen Idec’s Tecfidera for multiple sclerosis, setting the scene for a European three-way battle with Novartis’ Gilenya in the coming months.

Germany’s Pricing Revolution: Why The World Should Be Watching

Germany’s new early-benefit assessment system for all new drugs launched since Jan. 1, 2011, radically changes the status of Europe’s largest market. It was once a bastion of free (and thus relatively high) pricing, which firms used to signal their drugs’ value to other markets. Now, prices of new drugs will be negotiated between sponsors and the country’s association of statutory sick funds, on the basis of an added-benefit score determined by the G-BA, or Federal Joint Committee. Since those net prices will be made public, and many other countries reference German prices, there’s a real risk of a downward price spiral across Europe.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel